EDN1 and pulmonary arterial hypertension: According to the guidelines of the European Society of Cardiology, the currently available options to treat PAH target the three different pathways, which underlie PAH: (i) Increased concentration of endothelin-1, (ii) decreased concentration of nitric oxide, and (iii) decreased concentration of prostacyclin [13].